Overall rank by patents
#24,992
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 9 technology areas, active 2021–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G06N (COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS).
The verdict
Peptilogics holds 11 US patents across 9 technology areas, rank #24,992 of 50,000 tracked assignees.
Peptilogics, Inc. has been granted 11 US utility patents between 2021 and 2024, placing Peptilogics, Inc. at rank #24,992 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.4 claims per patent with primary concentration in G06N (COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS). As a US Corporation, Peptilogics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Peptilogics sits between Parker Hannifin Manufacturing Limited (11 patents, rank #24,988) and Peter Maccallum Cancer Institute (11 patents, rank #24,996) - the closest US assignees by grant volume. The composite Innovation Score of 53.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2024, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Peptilogics, Inc.'s 23.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Peptilogics, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Parker Hannifin Manufacturing Limited
11 patents
Pattern Bioscience, Inc.
11 patents
PendoTECH
11 patents
PeptiDream Inc.
11 patents
PerceptiMed, Inc.
11 patents
Percutaneous Cardiovascular Solutions Pty Ltd
11 patents
Pericom Semiconductor Corporation
11 patents
Peter MacCallum Cancer Institute
11 patents
Peptilogics, Inc.
11 patents
What this shows Peptilogics holds 11 patents at rank #24,992, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #24,992 in granted patent volume.
Other assignees with the most granted patents in Peptilogics's primary technology class.
Peptilogics's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
53 Top 9% higher than 91% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 9.1% |
| 2022 | 5 | 45.5% |
| 2023 | 2 | 18.2% |
| 2024 | 3 | 27.3% |
Top 9 of 9 technology areas
Overall rank by patents
#24,992
Across all tracked assignees
53.2 out of 100
How to use this portfolio
Peptilogics's 11 grants land it in the top 9% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.